Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer
September 26 2023 - 4:46PM
Mdxhealth Signs Research Collaboration with University of Oxford to
Assess the Correlation of the GPS Test with Prostate Cancer
Progression Following Treatment for Localized Prostate Cancer
NEWS RELEASE
September 26,
2023,
5:00PM EDT / 23:00
CET
Mdxhealth Signs Research
Collaboration with University of Oxford
to Assess the Correlation
of the GPS Test with Prostate Cancer Progression
Following Treatment
for Localized Prostate
Cancer
IRVINE, CA, and HERSTAL, BELGIUM –
September 26, 2023 –
MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage
precision diagnostics company, today announced a research
collaboration with the University of Oxford to investigate the
correlation between the Genomic Prostate Score (GPS) test and
prostate cancer progression following treatment for localized
prostate cancer.
Ian Mills, PhD, John Black Professor of
Prostate Cancer at University of
Oxford,
commented: "Prostate cancer is a
prevalent male cancer that can develop into metastases in certain
cases, underscoring the urgent need for improved risk
stratification through disease profiling and biological modeling.
We are excited to collaborate with mdxhealth to validate the GPS
test's potential to enhance risk assessment in men diagnosed with
localized prostate cancer."
As a pivotal part of this collaboration,
mdxhealth will conduct GPS testing on patient samples derived from
the Prostate Mechanisms of Progression and Treatment (ProMPT)
cohort. Initiated in 2002, the ProMPT collaborative translational
research group involves the cooperation of multiple cancer research
programs to collect biological samples and clinical data from
participants across the United Kingdom.
Michael K. McGarrity, CEO of
mdxhealth,
commented, “This groundbreaking
research partnership between mdxhealth and University of Oxford
marks a crucial step toward advancing the understanding of prostate
cancer progression and treatment outcomes. The outcomes of this
collaboration can pave the way for more tailored and effective
treatments for patients with localized prostate cancer. We firmly
believe that our Genomic Prostate Score test holds the potential to
accurately predict disease progression in patients undergoing
treatment for localized prostate cancer.”
About mdxhealth
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
For more information:
mdxhealth info@mdxhealth.com |
|
LifeSci
Advisors (IR & PR)US: +1 949 271
9223ir@mdxhealth.com |
|
This press release contains forward-looking
statements and estimates with respect to the anticipated future
performance of mdxhealth and the market in which it operates, all
of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or
phrases such as “potential,” “expect,” “will,” “goal,” “next,”
“potential,” “aim,” “explore,” “forward,” “future,” and “believes”
as well as similar expressions. Forward-looking statements
contained in this release include, but are not limited to,
statements regarding the acquisition of Oncotype DX® GPS prostate
cancer business from Exact Sciences including statements regarding
the anticipated benefits of the acquisition; statements regarding
expected future operating results; statements regarding product
development efforts; and statements regarding our strategies,
positioning, resources, capabilities and expectations for future
events or performance. Such statements and estimates are based on
assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but
may not prove to be correct. Actual events are difficult to
predict, may depend upon factors that are beyond the company’s
control, and may turn out to be materially different. Examples of
forward-looking statements include, among others, statements we
make regarding expected future operating results, product
development efforts, our strategies, positioning, resources,
capabilities and expectations for future events or performance.
Important factors that could cause actual results, conditions and
events to differ materially from those indicated in the
forward-looking statements include, among others, the following:
uncertainties associated with the coronavirus (COVID-19) pandemic,
including its possible effects on our operations, and the demand
for our products; our ability to successfully and profitably market
our products; the acceptance of our products and services by
healthcare providers; the willingness of health insurance companies
and other payers to cover our products and services and adequately
reimburse us for such products and services; our ability to obtain
and maintain regulatory approvals and comply with applicable
regulations; the possibility that the anticipated benefits from our
business acquisitions like our acquisition of the Oncotype DX® GPS
prostate cancer business will not be realized in full or at all or
may take longer to realize than expected; and the amount and nature
of competition for our products and services. Other important risks
and uncertainties are described in the Risk Factors sections of our
most recent Annual Report on Form 20-F and in our other reports
filed with the Securities and Exchange Commission. Mdxhealth
expressly disclaims any obligation to update any such
forward-looking statements in this release to reflect any change in
its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based
unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of mdxhealth in any jurisdiction. No
securities of mdxhealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Dec 2023 to Dec 2024